Selected article for: "acute ards respiratory distress syndrome and lopinavir hydroxychloroquine"

Author: Grimaldi, D.; Aissaoui, N.; Blonz, G.; Carbutti, G.; Courcelle, R.; Gaudry, S.; D'Hondt, A.; Higny, J.; Horlait, G.; Hraiech, S.; Lefebvre, L.; Lejeune, F.; Ly, A.; Piagnerelli, M.; Sauneuf, B.; Serck, N.; Soumagne, T.; Szychowiak, P.; Textoris, J.; Vandenbunder, B.; Vinsonneau, C.; Lascarrou, J. B.
Title: Characteristics and outcomes of Acute Respiratory Distress Syndrome related to COVID-19 in Belgian and French Intensive Care Units according to antiviral strategies. The COVADIS multicenter observational study.
  • Cord-id: 27t269pd
  • Document date: 2020_7_7
  • ID: 27t269pd
    Snippet: Background Limited data are available for antiviral therapy efficacy especially for the most severe patients under mechanical ventilation suffering from Covid-19 related Acute Respiratory Distress Syndrome (ARDS). Methods Observational multicenter cohort of patients with moderate to severe Covid-19 ARDS, comparing antiviral strategies (none, hydroxychloroquine (HCQ), lopinavir/ritonavir (L/R), others (combination or remdesivir). The primary end-point was the day-28 ventilator free days (VFD), pa
    Document: Background Limited data are available for antiviral therapy efficacy especially for the most severe patients under mechanical ventilation suffering from Covid-19 related Acute Respiratory Distress Syndrome (ARDS). Methods Observational multicenter cohort of patients with moderate to severe Covid-19 ARDS, comparing antiviral strategies (none, hydroxychloroquine (HCQ), lopinavir/ritonavir (L/R), others (combination or remdesivir). The primary end-point was the day-28 ventilator free days (VFD), patients which died before d28 were considered as having 0 VFD. The variable was dichotomized in patients still ventilated or dead at day 28 vs patients being extubated and alive at day 28 (VFD = or > 0). Results We analyzed 376 patients (80 with standard of care (SOC), 49 treated with L/R, 197 with HCQ, and 50 others). The median number of d28-VFD was 0 (IQR 0-13) and was different across the different groups (P=0.01), the SOC patients having the highest d28-VFD. A multivariate logistic regression including antiviral strategies, showed that age (OR 0.95 CI95%:0.93-0.98), male gender (OR 0.53 CI95%:0.31-0.93), Charlson score (OR 0.85 CI95%:0.73-0.99) and plateau pressure (OR 0.94 CI95%:0.88-0.99) were associated with having 0 d28-VFD whereas P/F ratio (OR 1.005 CI95%:1.001-1.010) was associated with having > or = 1 d28-VFD (ie. being extubated and alive). Acute kidney injury (AKI) was frequent (64%), its incidence was different across the patients groups (P=0.01). In a post-hoc logistic multivariate regression apart from demographics characteristics and comorbidities, the use of L/R (administered to 81 of 376 patients) was associated with occurrence of AKI (OR 2.07 CI95%:1.17-3.66) and need for renal replacement therapy (RRT). Conclusion In this observational study of moderate to severe Covid-19 ARDS patients, we did not observed a benefit of treating patients with any specific antiviral treatment. We observed an association between L/R treatment and occurrence of AKI and need for RRT.

    Search related documents:
    Co phrase search for related documents
    • acceptable safety profile and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8
    • acceptable safety profile and logistic regression: 1
    • acceptable safety profile and lopinavir ritonavir: 1
    • ace inhibitor and acute aki kidney injury: 1, 2, 3
    • ace inhibitor and acute kidney injury: 1, 2, 3, 4
    • ace inhibitor and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ace inhibitor and acute respiratory distress syndrome: 1, 2, 3, 4, 5
    • ace inhibitor and acute respiratory failure: 1
    • ace inhibitor and logistic regression: 1, 2, 3, 4, 5, 6, 7
    • acute aki kidney injury and logistic multivariate regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acute aki kidney injury and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute aki kidney injury and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7
    • acute aki kidney injury and lopinavir ritonavir treatment: 1, 2
    • acute kidney injury and logistic multivariate regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute kidney injury and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute kidney injury and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute kidney injury and lopinavir ritonavir treatment: 1, 2, 3, 4, 5
    • acute pathology and logistic multivariate regression: 1
    • acute pathology and logistic regression: 1